Interpreting Positive and Inverse Disproportionality Signals in Spontaneous Reporting Systems: A Claim-Strength Framework with Direction-Aware Evaluation

{"Disproportionality":[0],"analysis":[1],"of":[2,59,96,135,173,191,229,263],"spontaneous":[3],"reporting":[4,31,89,204],"systems":[5],"is":[6,90,168],"usually":[7],"used":[8],"to":[9,84,113,196,257],"identify":[10],"positive":[11,104,197],"signals,":[12],"meaning":[13],"drug-event":[14],"pairs":[15],"reported":[16,239],"more":[17],"often":[18],"than":[19],"expected.":[20],"The":[21,80],"same":[22,81,115,137],"statistical":[23],"structure":[24],"also":[25,194,209,245],"has":[26],"a":[27,74,184,211],"lower-reporting":[28],"side.":[29],"A":[30],"odds":[32],"ratio":[33],"(ROR)":[34],"above":[35],"unity":[36,44],"indicates":[37,45],"higher-than-expected":[38],"reporting,":[39],"whereas":[40],"an":[41],"ROR":[42,67,85],"below":[43],"lower-than-expected":[46,241],"reporting.":[47,242],"Neither":[48],"result":[49],"directly":[50],"estimates":[51],"incidence,":[52],"absolute":[53],"risk,":[54],"or":[55,77,159,205,249,265],"causality.":[56],"Existing":[57],"critiques":[58,190],"inverse":[60,106,192,235],"disproportionality":[61,107],"signals":[62,108,193,198,236],"rightly":[63],"warn":[64],"against":[65],"interpreting":[66],"<":[68],"1":[69],"as":[70,240],"protection,":[71],"risk":[72,266],"reduction,":[73],"beneficial":[75],"reaction,":[76],"therapeutic":[78],"effect.":[79],"caution":[82],"applies":[83],">":[86],"1.":[87],"Higher-than-expected":[88],"not,":[91],"by":[92],"itself,":[93],"causal":[94,206],"evidence":[95,141,218],"harm.":[97],"This":[98,118],"narrative":[99],"methodological":[100],"review":[101,182],"argues":[102],"that":[103,133,167,187],"and":[105,199,259],"should":[109],"be":[110,238],"interpreted":[111],"according":[112],"the":[114,136,171,174,181,216,221,227,230],"scientific":[116,130],"principles.":[117],"does":[119,146],"not":[120,147,225],"imply":[121],"symmetric":[122],"regulatory":[123,157],"action":[124],"thresholds.":[125],"In":[126],"this":[127,178,233],"review,":[128],"\\"symmetric":[129],"standards\\"":[131],"means":[132],"claims":[134],"strength":[138,172],"require":[139,268],"commensurate":[140],"in":[142,214],"both":[143],"directions;":[144],"it":[145,163],"mean":[148],"identical":[149],"case-level":[150],"information,":[151],"bias":[152],"mechanisms,":[153],"detectability,":[154],"predictive":[155],"value,":[156],"priority,":[158],"follow-up":[160,253],"procedures.":[161],"Instead,":[162],"calls":[164],"for":[165,252],"interpretation":[166],"consistent":[169],"with":[170],"claim.":[175],"To":[176],"make":[177],"approach":[179],"practical,":[180],"outlines":[183],"symmetry":[185],"check":[186],"asks":[188],"whether":[189,200],"apply":[195],"they":[201],"address":[202],"descriptive":[203],"interpretation.":[207],"It":[208],"proposes":[210],"claim-strength":[212],"framework":[213],"which":[215],"required":[217],"depends":[219],"on":[220,226],"claim":[222],"being":[223],"made,":[224],"direction":[228],"signal.":[231],"Under":[232],"approach,":[234],"may":[237,244],"They":[243],"support":[246],"hypothesis":[247],"generation":[248],"candidate":[250],"prioritization":[251],"evaluation":[254],"when":[255],"robust":[256],"comparator":[258],"sensitivity":[260],"analyses.":[261],"Claims":[262],"protection":[264],"reduction":[267],"external":[269],"validation.":[270]}

Authors

Institutions

Publication Details

Journal
Drug Safety
Published
2026-09-17
DOI
https://doi.org/10.1007/s40264-026-01726-x
Primary Topic
Pharmacovigilance and Adverse Drug Reactions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Interpreting Positive and Inverse Disproportionality Signals in Spontaneous Reporting Systems: A Claim-Strength Framework with Direction-Aware Evaluation

Yoshihiro Uesawa
Drug Safety
Pharmacovigilance and Adverse Drug Reactions
article

Interpreting Positive and Inverse Disproportionality Signals in Spontaneous Reporting Systems: A Claim-Strength Framework with Direction-Aware Evaluation

Yoshihiro Uesawa
article en

Abstract

Disproportionality analysis of spontaneous reporting systems is usually used to identify positive signals, meaning drug-event pairs reported more often than expected. The same statistical structure also has a lower-reporting side. A reporting odds ratio (ROR) above unity indicates higher-than-expected reporting, whereas an ROR below unity indicates lower-than-expected reporting. Neither result directly estimates incidence, absolute risk, or causality. Existing critiques of inverse disproportionality signals rightly warn against interpreting ROR < 1 as protection, risk reduction, a beneficial reaction, or therapeutic effect. The same caution applies to ROR > 1. Higher-than-expected reporting is not, by itself, causal evidence of harm. This narrative methodological review argues that positive and inverse disproportionality signals should be interpreted according to the same scientific principles. This does not imply symmetric regulatory action thresholds. In this review, "symmetric scientific standards" means that claims of the same strength require commensurate evidence in both directions; it does not mean identical case-level information, bias mechanisms, detectability, predictive value, regulatory priority, or follow-up procedures. Instead, it calls for interpretation that is consistent with the strength of the claim. To make this approach practical, the review outlines a symmetry check that asks whether critiques of inverse signals also apply to positive signals and whether they address descriptive reporting or causal interpretation. It also proposes a claim-strength framework in which the required evidence depends on the claim being made, not on the direction of the signal. Under this approach, inverse signals may be reported as lower-than-expected reporting. They may also support hypothesis generation or candidate prioritization for follow-up evaluation when robust to comparator and sensitivity analyses. Claims of protection or risk reduction require external validation.

Drug Safety
Meiji Pharmaceutical University (JP)
Peace, Justice and strong institutions
Openalex Percentile: Top 13%
Pharmacovigilance and Adverse Drug Reactions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.